Patent · US Expired

Pharmaceutical compositions comprising erythropoietin for treatment of cancer

US6579525B1 · kind B1 · utility

7Cited by
0References
6Claims
0Family size

Assignees

Inventors

Key dates

Filing dateOct 5, 2000
Grant dateJun 17, 2003
Priority date
Expiry dateOct 5, 2020

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/02
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Pharmaceutical compositions comprising erythropoietin are provided for treatment of cancer, particularly for treatment of multiple myeloma. Erythropoietin was found to be effective for inhibition of tumor growth, triggering of tumor regression, stimulation of the natural immunological defense against cancer and/or inhibition of cancer cell metastasis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.